MBX Biosciences Doses First Patient in Phase 2 Avail Trial of MBX 2109 for the Treatment of Hypoparathyroidism

Monday, August 12, 2024 1 min read

Key Takeaway: MBX Biosciences Doses First Patient in Phase 2 Avail Trial of MBX 2109 for the Treatment of Hypoparathyroidism

Full Press Release Details

MBX Biosciences Doses First Patient in Phase 2 Avail Trial of MBX 2109 for the Treatment of Hypoparathyroidism.